OraQuick® HIV Self-Test Now Approved for Use in Adolescents
OraSure Technologies announced the expansion of its OraQuick® HIV Self-Test approved age range to include individuals 14 years and older, down from the previous minimum age of 17. This development is particularly significant as CDC data shows that 19% of new HIV diagnoses in the United States occur among young people aged 13-24, with only 6% of high school students ever being tested for HIV. Almost half of young people with HIV are unaware of their status.
The OraQuick® HIV Self-Test has been available to U.S. consumers since 2012. The test includes comprehensive educational materials and care information to help users make informed decisions regardless of results. This expansion aims to increase HIV testing accessibility among adolescents and support early connection to care for those who test positive.
OraSure Technologies ha annunciato l'ampliamento della fascia di età approvata per il suo OraQuick® HIV Self-Test, ora inclusiva di individui dai 14 anni in su, rispetto al precedente limite minimo di 17 anni. Questo sviluppo è particolarmente significativo poiché i dati del CDC mostrano che il 19% delle nuove diagnosi di HIV negli Stati Uniti avviene tra i giovani di età compresa tra 13 e 24 anni, con solo il 6% degli studenti delle scuole superiori che ha mai effettuato un test per l'HIV. Quasi la metà dei giovani con HIV non è a conoscenza del proprio stato.
Il test OraQuick® HIV Self-Test è disponibile per i consumatori statunitensi dal 2012. Il test include materiali educativi e informazioni sulla cura complete per aiutare gli utenti a prendere decisioni informate indipendentemente dai risultati. Questa espansione mira ad aumentare l'accessibilità al test HIV tra gli adolescenti e a supportare una connessione precoce con le cure per coloro che risultano positivi.
OraSure Technologies anunció la expansión de su rango de edad aprobado para el OraQuick® HIV Self-Test, que ahora incluye a individuos de 14 años o más, en lugar de los 17 años anteriores. Este desarrollo es particularmente significativo ya que los datos del CDC muestran que el 19% de los nuevos diagnósticos de HIV en los Estados Unidos ocurren entre jóvenes de 13 a 24 años, con solo el 6% de los estudiantes de secundaria que alguna vez se han sometido a una prueba de HIV. Casi la mitad de los jóvenes con HIV no son conscientes de su estado.
El test OraQuick® HIV Self-Test ha estado disponible para los consumidores de EE. UU. desde 2012. La prueba incluye materiales educativos completos e información sobre cuidados para ayudar a los usuarios a tomar decisiones informadas independientemente de los resultados. Esta expansión tiene como objetivo aumentar el acceso a las pruebas de HIV entre los adolescentes y apoyar la conexión temprana con la atención para aquellos que den positivo.
오라쉐어 테크놀로지스는 오라퀵® HIV 자가 검사의 승인된 연령 범위를 14세 이상으로 확장한다고 발표했습니다. 이전 최소 연령은 17세였습니다. 이 개발은 CDC 데이터에 따르면 미국에서 새로운 HIV 진단의 19%가 13세에서 24세 사이의 청소년 사이에서 발생하며 고등학생의 6%만이 HIV 검사를 받은 것으로 나타나기 때문에 특히 중요합니다. HIV에 감염된 청소년의 거의 절반이 자신의 감염 여부를 알지 못합니다.
오라퀵® HIV 자가 검사는 2012년부터 미국 소비자들에게 제공되었습니다. 이 검사는 사용자가 결과에 관계없이 정보에 입각한 결정을 내리는 데 도움을 줄 수 있도록 포괄적인 교육 자료와 치료 정보를 포함하고 있습니다. 이 확장은 청소년들 사이에서 HIV 검사 접근성을 높이고 양성 판정을 받은 이들이 조기에 치료에 연결될 수 있도록 돕는 것을 목표로 하고 있습니다.
OraSure Technologies a annoncé l'expansion de la tranche d'âge approuvée pour son OraQuick® HIV Self-Test, qui inclut désormais les personnes de 14 ans et plus, contre un âge minimum précédent de 17 ans. Ce développement est particulièrement significatif puisque les données des CDC montrent que 19% des nouveaux diagnostics de VIH aux États-Unis concernent des jeunes âgés de 13 à 24 ans, avec seulement 6% des lycéens ayant jamais été testés pour le VIH. Près de la moitié des jeunes atteints du VIH ne sont pas conscients de leur statut.
Le test OraQuick® HIV Self-Test est disponible pour les consommateurs américains depuis 2012. Le test comprend des matériaux éducatifs complets et des informations sur les soins pour aider les utilisateurs à prendre des décisions éclairées, quel que soit le résultat. Cette expansion vise à accroître l'accessibilité des tests VIH parmi les adolescents et à soutenir une connexion précoce aux soins pour ceux qui obtiennent un résultat positif.
OraSure Technologies hat die Erweiterung des genehmigten Altersbereichs für den OraQuick® HIV Selbsttest angekündigt, der jetzt Personen ab 14 Jahren umfasst, im Vergleich zum vorherigen Mindestalter von 17 Jahren. Diese Entwicklung ist besonders bedeutend, da Daten des CDC zeigen, dass 19% der neuen HIV-Diagnosen in den Vereinigten Staaten bei jungen Menschen im Alter von 13 bis 24 Jahren erfolgen, wobei nur 6% der Schüler in der Oberstufe jemals auf HIV getestet wurden. Fast die Hälfte der jungen Menschen mit HIV ist sich ihres Status nicht bewusst.
Der OraQuick® HIV Selbsttest ist seit 2012 für US-Verbraucher erhältlich. Der Test enthält umfassende Bildungsangebote und Informationen zur Versorgung, die den Nutzern helfen, informierte Entscheidungen unabhängig von den Ergebnissen zu treffen. Diese Erweiterung zielt darauf ab, die Zugänglichkeit von HIV-Tests unter Jugendlichen zu erhöhen und eine frühe Verbindung zur Versorgung für diejenigen zu unterstützen, die positiv getestet werden.
- Expanded market reach to include adolescents aged 14-16
- Addresses an underserved market segment with 19% of new HIV diagnoses
- Potential for increased test adoption given low current testing rates among teenagers
- None.
Insights
The FDA's approval to expand OraQuick® HIV Self-Test usage to adolescents aged 14 and above represents a important development in HIV screening accessibility. The 19% of new HIV diagnoses among young people aged 13-24, coupled with only 6% of high school students ever being tested, underscores a significant gap in early detection. This expansion addresses a critical public health need, particularly considering that nearly half of HIV-positive youth are unaware of their status.
The test's proven track record since 2012 in the direct-to-consumer market demonstrates its reliability and effectiveness. The inclusion of educational materials and care linkage information in the packaging enhances its value as a comprehensive screening tool. This approval could significantly impact early intervention rates and treatment outcomes in the adolescent demographic, where privacy concerns often create barriers to traditional testing methods.
From a market perspective, this regulatory expansion opens up a substantial new demographic for OraSure Technologies. With approximately 42 million adolescents in the U.S., this approval could significantly expand the company's addressable market. The timing aligns with increased awareness of youth healthcare needs and could drive revenue growth in the HIV testing segment.
However, market penetration will depend on factors such as pricing strategy, distribution channels and marketing efforts targeting both adolescents and their healthcare providers. The company's established presence in the self-testing market since 2012 provides a strong foundation for this expansion. For a company with a market cap of <money>280</money> million, this approval could represent a meaningful growth catalyst, particularly given the untapped potential in adolescent HIV testing.
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick® HIV Self-Test. Previously the test was approved for use in those 17 and older.
According to the most recent data available from the Centers for Disease Control & Prevention, it is estimated that 19 percent of new HIV diagnoses in the United States were among young people aged 13 to 24, and only 6 percent of high school students have ever been tested for HIV. Almost half of young people with HIV do not know that they have it.
“Increasing access to different testing options is critical to ending the HIV epidemic for all people, and early connection to care is essential for adolescents who test positive for HIV,” said Carrie Eglinton Manner, President and CEO of OraSure Technologies. “We are pleased that our OraQuick® HIV Self-Test can now be used within this younger population who needs it, and we are proud of the work we have done to promote HIV testing, help people know their HIV status, and stop the stigma of infection. This approval will allow us to expand access to help those who need it.”
The OraQuick® HIV Self-Test has been available direct to consumers in the U.S. since 2012. Since its launch, OraSure has been committed to providing consumers with access to critical information and connection to care. The packaging contains robust educational material and linkage to care information, giving individuals information that they can use to make informed decisions, regardless of the test result.
About OraSure Technologies, Inc.
OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.
Forward-Looking Statement
This press release contains certain forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: our ability to satisfy customer demand; ability to market and sell products, whether through our internal, direct sales force or third parties; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; ability to comply with applicable regulatory requirements; ability to meet increased demand for OraSure’s products; competition from new or better technology or lower cost products; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention or other agencies; ability to obtain and maintain new or existing product distribution channels; impact of negative economic conditions; ability to maintain sustained profitability; changes in international, federal or state laws and regulations; equipment failures and ability to obtain needed raw materials and components. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.
| Investor Contact: | Media Contact: |
| Jason Plagman | Amy Koch |
| Vice President, Investor Relations | Director, Corporate Communications |
| investorinfo@orasure.com | media@orasure.com |
FAQ
What is the new age requirement for OraQuick HIV Self-Test (OSUR)?
How many high school students have been tested for HIV according to CDC data?
What percentage of new HIV diagnoses are among young people aged 13-24?
When did the OraQuick HIV Self-Test (OSUR) first become available to U.S. consumers?
What percentage of young people with HIV are unaware of their status?
